Targeted therapies for glioblastoma in adults and kids
Official title: Harvard/Stanford GTN Program: Novel targeted therapeutics for glioblastoma
Funded at Brigham and Women's Hospital · NIH-11608562 · Data updated 2026-11-12
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $927,126 |
| NIH project number | 3U19CA264504-05S1 |
| Project ID | NIH-11608562 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with glioma, including pediatric and young adult cases, who may enroll in related clinical trials or receive future targeted therapies.
✕Less likely to help
Patients with glioma who do not meet trial eligibility or who do not respond to the studied therapies may not benefit.
What this research studies
This program brings together three focused projects to advance glioma treatment. Project 1 works on pediatric low-grade gliomas, using a brain-penetrant drug and new tools to predict which children will respond best. Project 2 targets the deadliest childhood brain tumor by exploiting a DNA repair weakness and testing a lead drug in a clinical trial. The work combines biology, chemistry, and AI to personalize therapy and improve outcomes for patients with gliomas.
Why it matters
Potential benefit: If successful, this program could lead to more effective, personalize treatments for glioma patients, including children.
How similar studies have gone: Prior studies show promise for targeted RAF inhibitors in gliomas and AI-assisted prediction tools, but results are still emerging.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Batchelor, Tracy T — Brigham and Women's Hospital
- Study coordinator: Batchelor, Tracy T
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
-
Role of a brain tumor RNA in glioblastoma where a unique lncRNA may drive cancer cells
A small, focused NIH grant explores how a brain cancer–related RNA called LINC01896 might control the growth of glioblastoma stem cells and influence treatment resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.